ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer

Despite initial benefits in treating HER2-positive breast cancer patients with lapatinib, resistance is prevalent. Here the authors show that lapatinib resistance can be ascribed to mTOR-mediated re-activation of ERRα and to the consequent induction of a metabolic adaptation.

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Geneviève Deblois, Harvey W. Smith, Ingrid S. Tam, Simon-Pierre Gravel, Maxime Caron, Paul Savage, David P. Labbé, Louis R. Bégin, Michel L. Tremblay, Morag Park, Guillaume Bourque, Julie St-Pierre, William J. Muller, Vincent Giguère
Format: article
Langue:EN
Publié: Nature Portfolio 2016
Sujets:
Science
Q
Accès en ligne:https://doaj.org/article/a807b71593d5451987bf6593688f61a3
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/a807b71593d5451987bf6593688f61a3

Documents similaires